AbbVie Inc. (NYSE:ABBV) Shares Acquired by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 5.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 177,739 shares of the company’s stock after purchasing an additional 8,550 shares during the period. AbbVie makes up approximately 0.7% of Integrated Investment Consultants LLC’s portfolio, making the stock its 10th biggest holding. Integrated Investment Consultants LLC’s holdings in AbbVie were worth $31,584,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABBV. Sei Investments Co. boosted its stake in shares of AbbVie by 11.2% in the 2nd quarter. Sei Investments Co. now owns 484,279 shares of the company’s stock worth $83,064,000 after buying an additional 48,722 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in shares of AbbVie by 16.6% in the 2nd quarter. Summit Trail Advisors LLC now owns 20,558 shares of the company’s stock worth $3,526,000 after buying an additional 2,924 shares during the last quarter. TPG Advisors LLC purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $366,000. Tcwp LLC raised its holdings in shares of AbbVie by 12.0% in the 2nd quarter. Tcwp LLC now owns 2,936 shares of the company’s stock worth $504,000 after purchasing an additional 315 shares during the period. Finally, Westwood Holdings Group Inc. raised its holdings in shares of AbbVie by 1.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 11,380 shares of the company’s stock worth $1,952,000 after purchasing an additional 130 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of a number of research reports. Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price target on the stock. in a report on Thursday, December 5th. Morgan Stanley lowered their price target on shares of AbbVie from $231.00 to $224.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. UBS Group lifted their price target on shares of AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company boosted their target price on shares of AbbVie to $195.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $205.50.

AbbVie Stock Down 1.3 %

ABBV opened at $171.49 on Friday. The company has a fifty day moving average price of $175.78 and a 200-day moving average price of $184.60. The firm has a market capitalization of $303.05 billion, a P/E ratio of 59.55, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.28 billion. During the same period in the previous year, the business earned $2.95 EPS. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts expect that AbbVie Inc. will post 10.06 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s dividend payout ratio is currently 215.28%.

Insider Activity at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is owned by insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.